Seattle Cancer Care Alliance (SCCA) nurses will join their nursing colleagues throughout the country to present their research at the 2019 Oncology Nursing Society (ONS) Congress, which is the society’s annual conference. ONS is a professional association of more than 39,000 members committed to promoting excellence in oncology nursing.
More than a dozen Seattle Cancer Care Alliance (SCCA) and Fred Hutch physicians and researchers who are leaders in breast oncology will be at the San Antonio Breast Cancer Symposium December 4-8. The symposium provides the latest information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.
SCCA among first cancer treatment centers in country - and only in NW - to offer axi-cel (YESCARTA™) -- ground-breaking new immunotherapy
Seattle Cancer Care Alliance (SCCA) has been a leader in immunotherapy since it was first introduced as a form of treatment for certain cancers decades ago. Today, we’ve been selected as the only certified treatment center in the Northwest to offer axicabtagene ciloleucel (axi-cel, also known by the brand name YESCARTA™), a new immunotherapy that uses engineered cell therapy to harnesses the power of a patient’s own immune system to treat adults with aggressive non-Hodgkin lymphoma (NHL).
Each day, new research, innovations and stories are published about cancer and those who it impacts. Here's a roundup of recent items in the news. Cancer treatment isn't one size fits all. The Hartford Courant reports on an evolving technology that gives doctors even more information about a patient's cancer cells. It's potentially one more way our doctors can develop personalized treatment plans.
IsoPlexis is developing a system that analyzes patients’ tumors cell by cell to determine how effective or toxic a treatment would be and to help guide doctors’ decisions about mixing different cancer therapies.
Developments about former President Jimmy Carter’s melanoma diagnosis and the subsequent story about his positive response to treatment has made me pause and reflect on the extraordinary progress in a remarkably short period of time, both in the treatment of what used to be considered one of the most deadly cancers and in the very rapid advancement of immunotherapy. In August 2015, President Carter was diagnosed with Stage IV melanoma that had spread to his liver and brain. He had surgery for the tumors in the liver and focused radiation for those in his brain followed by immunotherapy with a drug – pembrolizumab – classified as an anti-PD-1 antibody. A happy update indicated that President Carter was having an excellent response to the immunotherapy: there have been no new tumors.